Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Also see the archival list of Science's Compass: Enhanced Perspectives
CANCER: Enhanced: Addiction to Oncogenes--the Achilles Heal of Cancer
I. Bernard Weinstein
A series of recent studies are providing tantalizing hints of new therapeutic approaches for combating cancer. In his Perspective, Weinstein discusses new work (Jain et al.) demonstrating that even brief inactivation of an oncogene can permanently reverse the malignant phenotype of some types of tumor.
The author is at the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA. E-mail: weinstei{at}cancercenter.columbia.edu
The editors suggest the following Related Resources on Science sites:
In Science Magazine
REPORTS
Meenakshi Jain, Constadina Arvanitis, Kenneth Chu, William Dewey, Edith Leonhardt, Maxine Trinh, Christopher D. Sundberg, J. Michael Bishop, and Dean W. Felsher (5 July 2002) Science297 (5578), 102.
[DOI: 10.1126/science.1071489] |Abstract »|Full Text »|PDF »|Supplemental Data »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction.
F. Shima, Y. Yoshikawa, M. Ye, M. Araki, S. Matsumoto, J. Liao, L. Hu, T. Sugimoto, Y. Ijiri, A. Takeda, et al. (2013)
PNAS
110, 8182-8187
|Abstract »|Full Text »|PDF »
A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.
K. Masui, B. Gini, J. Wykosky, C. Zanca, P. S. Mischel, F. B. Furnari, and W. K. Cavenee (2013)
Carcinogenesis
34, 725-738
|Abstract »|Full Text »|PDF »
BIM, PUMA, and the Achilles' Heel of Oncogene Addiction.
A. Roulston, W. J. Muller, and G. C. Shore (2013)
Science Signaling
6, pe12
|Abstract »|Full Text »|PDF »
PUMA and BIM Are Required for Oncogene Inactivation-Induced Apoptosis.
G. R. Bean, Y. T. Ganesan, Y. Dong, S. Takeda, H. Liu, P. M. Chan, Y. Huang, L. A. Chodosh, G. P. Zambetti, J. J.- D. Hsieh, et al. (2013)
Science Signaling
6, ra20
|Abstract »|Full Text »|PDF »
Fas expression by tumor stroma is required for cancer eradication.
J. J. Listopad, T. Kammertoens, K. Anders, B. Silkenstedt, G. Willimsky, K. Schmidt, A. A. Kuehl, C. Loddenkemper, and T. Blankenstein (2013)
PNAS
110, 2276-2281
|Abstract »|Full Text »|PDF »
N. L. Solimini, A. C. Liang, C. Xu, N. N. Pavlova, Q. Xu, T. Davoli, M. Z. Li, K.-K. Wong, and S. J. Elledge (2013)
PNAS
110, E407-E414
|Abstract »|Full Text »|PDF »
Molecular Pathways: Comparing the Effects of Drugs and T Cells to Effectively Target Oncogenes.
Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth.
F. Harbinski, V. J. Craig, S. Sanghavi, D. Jeffery, L. Liu, K. A. Sheppard, S. Wagner, C. Stamm, A. Buness, C. Chatenay-Rivauday, et al. (2012)
Cancer Discovery
2, 948-959
|Abstract »|Full Text »|PDF »
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
H. Greulich, B. Kaplan, P. Mertins, T.-H. Chen, K. E. Tanaka, C.-H. Yun, X. Zhang, S.-H. Lee, J. Cho, L. Ambrogio, et al. (2012)
PNAS
109, 14476-14481
|Abstract »|Full Text »|PDF »
Promising Personalized Therapeutic Options for Diffuse Large B-cell Lymphoma Subtypes with Oncogene Addictions.
J. J. Steinhardt and R. B. Gartenhaus (2012)
Clin. Cancer Res.
18, 4538-4548
|Abstract »|Full Text »|PDF »
The evolving concept of cancer and metastasis stem cells.
Phosphoproteomic Analysis of Leukemia Cells under Basal and Drug-treated Conditions Identifies Markers of Kinase Pathway Activation and Mechanisms of Resistance.
M. P. Alcolea, P. Casado, J.-C. Rodriguez-Prados, B. Vanhaesebroeck, and P. R. Cutillas (2012)
Mol. Cell. Proteomics
11, 453-466
|Abstract »|Full Text »|PDF »
A systematic approach to therapeutic target selection in oesophago-gastric cancer.
A. L. Paterson, N. B. Shannon, P. Lao-Sirieix, C.-A. J. Ong, C. J. Peters, M. O'Donovan, and R. C. Fitzgerald (2012)
Gut
|Abstract »|Full Text »
Key concepts in glioblastoma therapy.
J. Bartek Jr, K. Ng, J. Bartek, W. Fischer, B. Carter, and C. C. Chen (2012)
J. Neurol. Neurosurg. Psychiatry
83, 753-760
|Abstract »|Full Text »|PDF »
New Approaches to Targeted Therapy in Lung Cancer.
PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS.
M. P. Stokes, C. L. Farnsworth, A. Moritz, J. C. Silva, X. Jia, K. A. Lee, A. Guo, R. D. Polakiewicz, and M. J. Comb (2012)
Mol. Cell. Proteomics
11, 187-201
|Abstract »|Full Text »|PDF »
Attacking a Nexus of the Oncogenic Circuitry by Reversing Aberrant eIF4F-Mediated Translation.
P. B. Bitterman and V. A. Polunovsky (2012)
Mol. Cancer Ther.
11, 1051-1061
|Abstract »|Full Text »|PDF »
Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities.
P. Perez-Moreno, E. Brambilla, R. Thomas, and J.-C. Soria (2012)
Clin. Cancer Res.
18, 2443-2451
|Abstract »|Full Text »|PDF »
Cigarette Smoke Induces Aberrant EGF Receptor Activation That Mediates Lung Cancer Development and Resistance to Tyrosine Kinase Inhibitors.
S. Filosto, C. R. Becker, and T. Goldkorn (2012)
Mol. Cancer Ther.
11, 795-804
|Abstract »|Full Text »|PDF »
Cyclin-Dependent Kinase 7/9 Inhibitor SNS-032 Abrogates FIP1-like-1 Platelet-Derived Growth Factor Receptor {alpha} and Bcr-Abl Oncogene Addiction in Malignant Hematologic Cells.
Y. Wu, C. Chen, X. Sun, X. Shi, B. Jin, K. Ding, S.-C. J. Yeung, and J. Pan (2012)
Clin. Cancer Res.
18, 1966-1978
|Abstract »|Full Text »|PDF »
Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma.
L. Lin, A. J. Bass, W. W. Lockwood, Z. Wang, A. L. Silvers, D. G. Thomas, A. C. Chang, J. Lin, M. B. Orringer, W. Li, et al. (2012)
PNAS
109, 4251-4256
|Abstract »|Full Text »|PDF »
ROS1 Rearrangements in Lung Cancer: A New Genomic Subset of Lung Adenocarcinoma.
P. A. Janne and M. Meyerson (2012)
J. Clin. Oncol.
30, 878-879
|Full Text »|PDF »
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine.
Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212.
J. Jing, J. Greshock, J. D. Holbrook, A. Gilmartin, X. Zhang, E. McNeil, T. Conway, C. Moy, S. Laquerre, K. Bachman, et al. (2012)
Mol. Cancer Ther.
11, 720-729
|Abstract »|Full Text »|PDF »
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
A. Hamilton, G. V. Helgason, M. Schemionek, B. Zhang, S. Myssina, E. K. Allan, F. E. Nicolini, C. Muller-Tidow, R. Bhatia, V. G. Brunton, et al. (2012)
Blood
119, 1501-1510
|Abstract »|Full Text »|PDF »
An emerging toolkit for targeted cancer therapies.
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis.
J. D. Kessler, K. T. Kahle, T. Sun, K. L. Meerbrey, M. R. Schlabach, E. M. Schmitt, S. O. Skinner, Q. Xu, M. Z. Li, Z. C. Hartman, et al. (2012)
Science
335, 348-353
|Abstract »|Full Text »|PDF »
Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways.
H.-F. Yuen, K.-K. Chan, C. Grills, J. T. Murray, A. Platt-Higgins, O. S. Eldin, K. O'Byrne, P. Janne, D. A. Fennell, P. G. Johnston, et al. (2012)
Clin. Cancer Res.
18, 380-391
|Abstract »|Full Text »|PDF »
An inducible krasV12 transgenic zebrafish model for liver tumorigenesis and chemical drug screening.
A. T. Nguyen, A. Emelyanov, C. H. V. Koh, J. M. Spitsbergen, S. Parinov, and Z. Gong (2012)
Dis. Model. Mech.
5, 63-72
|Abstract »|Full Text »|PDF »
Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers.
H. W. Cheung, J. Du, J. S. Boehm, F. He, B. A. Weir, X. Wang, M. Butaney, L. V. Sequist, B. Luo, J. A. Engelman, et al. (2011)
Cancer Discovery
1, 608-625
|Abstract »|Full Text »|PDF »
Overexpressed HER2 in NSCLC is a Possible Therapeutic Target of EGFR Inhibitors.
N. ISE, K. OMI, D. NAMBARA, S. HIGASHIYAMA, and K. GOISHI (2011)
Anticancer Res
31, 4155-4161
|Abstract »|Full Text »|PDF »
Chronic Activation of Wild-Type Epidermal Growth Factor Receptor and Loss of Cdkn2a Cause Mouse Glioblastoma Formation.
J. Acquaviva, H. J. Jun, J. Lessard, R. Ruiz, H. Zhu, M. Donovan, S. Woolfenden, A. Boskovitz, A. Raval, R. T. Bronson, et al. (2011)
Cancer Res.
71, 7198-7206
|Abstract »|Full Text »|PDF »
New Strategies for Treatment of ALK-Rearranged Non-Small Cell Lung Cancers.
Quantitative Chemical Proteomics Reveals New Potential Drug Targets in Head and Neck Cancer.
Z. Wu, J. B. Doondeea, A. M. Gholami, M. C. Janning, S. Lemeer, K. Kramer, S. A. Eccles, S. M. Gollin, R. Grenman, A. Walch, et al. (2011)
Mol. Cell. Proteomics
10, M111.011635
|Abstract »|Full Text »|PDF »
Is Co-option a Prevailing Mechanism during Cancer Progression?.
Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.
P. S. Choi, J. van Riggelen, A. J. Gentles, P. Bachireddy, K. Rakhra, S. J. Adam, S. K. Plevritis, and D. W. Felsher (2011)
PNAS
108, 17432-17437
|Abstract »|Full Text »|PDF »
Striking a Balance Between Feasible and Realistic Biological Models.
A. Califano (2011)
Science Translational Medicine
3, 103ps39
|Full Text »|PDF »
Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation.
P. T. Tran, P. K. Bendapudi, H. J. Lin, P. Choi, S. Koh, J. Chen, G. Horng, N. P. Hughes, L. H. Schwartz, V. A. Miller, et al. (2011)
Science Translational Medicine
3, 103ra99
|Abstract »|Full Text »|PDF »
Acquired Drug Resistance to Vascular Endothelial Growth Factor Receptor 2 Tyrosine Kinase Inhibitor in Human Vascular Endothelial Cells.
T. ARAO, K. MATSUMOTO, K. FURUTA, K. KUDO, H. KANEDA, T. NAGAI, K. SAKAI, Y. FUJITA, D. TAMURA, K. AOMATSU, et al. (2011)
Anticancer Res
31, 2787-2796
|Abstract »|Full Text »|PDF »
Liposomal Delivery of MicroRNA-7-Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells.
K. Rai, N. Takigawa, S. Ito, H. Kashihara, E. Ichihara, T. Yasuda, K. Shimizu, M. Tanimoto, and K. Kiura (2011)
Mol. Cancer Ther.
10, 1720-1727
|Abstract »|Full Text »|PDF »
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling.
N. Wagle, C. Emery, M. F. Berger, M. J. Davis, A. Sawyer, P. Pochanard, S. M. Kehoe, C. M. Johannessen, L. E. MacConaill, W. C. Hahn, et al. (2011)
J. Clin. Oncol.
29, 3085-3096
|Abstract »|Full Text »|PDF »
Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma.
Y. Yatabe, K. Matsuo, and T. Mitsudomi (2011)
J. Clin. Oncol.
29, 2972-2977
|Abstract »|Full Text »|PDF »
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.
J. Zuber, A. R. Rappaport, W. Luo, E. Wang, C. Chen, A. V. Vaseva, J. Shi, S. Weissmueller, C. Fellman, M. J. Taylor, et al. (2011)
Genes & Dev.
25, 1628-1640
|Abstract »|Full Text »|PDF »
Expression of the Adenovirus Early Gene 1A Transcription-Repression Domain Alone Downregulates HER2 and Results in the Death of Human Breast Cancer Cells Upregulated for the HER2 Proto-Oncogene.
NID2 and HOXA9 Promoter Hypermethylation as Biomarkers for Prevention and Early Detection in Oral Cavity Squamous Cell Carcinoma Tissues and Saliva.
R. Guerrero-Preston, E. Soudry, J. Acero, M. Orera, L. Moreno-Lopez, G. Macia-Colon, A. Jaffe, M. Berdasco, C. Ili-Gangas, P. Brebi-Mieville, et al. (2011)
Cancer Prevention Research
4, 1061-1072
|Abstract »|Full Text »|PDF »
How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers.
Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis.
X. Tang, H. Kadara, C. Behrens, D. D. Liu, Y. Xiao, D. Rice, A. F. Gazdar, J. Fujimoto, C. Moran, M. Varella-Garcia, et al. (2011)
Clin. Cancer Res.
17, 2434-2443
|Abstract »|Full Text »|PDF »
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors.
L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, et al. (2011)
Science Translational Medicine
3, 75ra26
|Abstract »|Full Text »|PDF »
Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction.
S. Benvenuti, L. Lazzari, A. Arnesano, G. Li Chiavi, A. Gentile, and P. M. Comoglio (2011)
Cancer Res.
71, 1945-1955
|Abstract »|Full Text »|PDF »
Breaking Evolution's Chains: The Prospect of Deliberate Genetic Modification in Humans.
KRIBB11 Inhibits HSP70 Synthesis through Inhibition of Heat Shock Factor 1 Function by Impairing the Recruitment of Positive Transcription Elongation Factor b to the hsp70 Promoter.
Y. J. Yoon, J. A. Kim, K. D. Shin, D.-S. Shin, Y. M. Han, Y. J. Lee, J. S. Lee, B.-M. Kwon, and D. C. Han (2011)
J. Biol. Chem.
286, 1737-1747
|Abstract »|Full Text »|PDF »
Role of MSK1 in the Malignant Phenotype of Ras-transformed Mouse Fibroblasts.
B. Perez-Cadahia, B. Drobic, P. S. Espino, S. He, S. Mandal, S. Healy, and J. R. Davie (2011)
J. Biol. Chem.
286, 42-49
|Abstract »|Full Text »|PDF »
The Biological Framework: Translational Research from Bench to Clinic.
Quantitative Proteomics Discloses MET Expression in Mitochondria as a Direct Target of MET Kinase Inhibitor in Cancer Cells.
T. Guo, Y. Zhu, C. S. Gan, S. S. Lee, J. Zhu, H. Wang, X. Li, J. Christensen, S. Huang, O. L. Kon, et al. (2010)
Mol. Cell. Proteomics
9, 2629-2641
|Abstract »|Full Text »|PDF »
The Biological Framework: Translational Research from Bench to Clinic.
p27Kip1 Mediates Addiction of Ovarian Cancer Cells to MYCC (c-MYC) and Their Dependence on MYC Paralogs.
T. Prathapam, A. Aleshin, Y. Guan, J. W. Gray, and G. S. Martin (2010)
J. Biol. Chem.
285, 32529-32538
|Abstract »|Full Text »|PDF »
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.
C. S.-O. Attolini, Y.-K. Cheng, R. Beroukhim, G. Getz, O. Abdel-Wahab, R. L. Levine, I. K. Mellinghoff, and F. Michor (2010)
PNAS
107, 17604-17609
|Abstract »|Full Text »|PDF »
MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors.
V. Cepero, J. R. Sierra, S. Corso, E. Ghiso, L. Casorzo, T. Perera, P. M. Comoglio, and S. Giordano (2010)
Cancer Res.
70, 7580-7590
|Abstract »|Full Text »|PDF »
Lung Injury and Cancer: Mechanistic Insights into Ceramide and EGFR Signaling under Cigarette Smoke.
Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases.
A. Moritz, Y. Li, A. Guo, J. Villen, Y. Wang, J. MacNeill, J. Kornhauser, K. Sprott, J. Zhou, A. Possemato, et al. (2010)
Science Signaling
3, ra64
|Abstract »|Full Text »|PDF »
Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors.
J. N. Andersen, S. Sathyanarayanan, A. Di Bacco, A. Chi, T. Zhang, A. H. Chen, B. Dolinski, M. Kraus, B. Roberts, W. Arthur, et al. (2010)
Science Translational Medicine
2, 43ra55
|Abstract »|Full Text »|PDF »
Sphingosine Kinase 1 Induces Tolerance to Human Epidermal Growth Factor Receptor 2 and Prevents Formation of a Migratory Phenotype in Response to Sphingosine 1-Phosphate in Estrogen Receptor-Positive Breast Cancer Cells.
J. S. Long, J. Edwards, C. Watson, S. Tovey, K. M. Mair, R. Schiff, V. Natarajan, N. J. Pyne, and S. Pyne (2010)
Mol. Cell. Biol.
30, 3827-3841
|Abstract »|Full Text »|PDF »
Structural Basis for Conformational Dynamics of GTP-bound Ras Protein.
F. Shima, Y. Ijiri, S. Muraoka, J. Liao, M. Ye, M. Araki, K. Matsumoto, N. Yamamoto, T. Sugimoto, Y. Yoshikawa, et al. (2010)
J. Biol. Chem.
285, 22696-22705
|Abstract »|Full Text »|PDF »
The interaction between Myc and Miz1 is required to antagonize TGF{beta}-dependent autocrine signaling during lymphoma formation and maintenance.
J. van Riggelen, J. Muller, T. Otto, V. Beuger, A. Yetil, P. S. Choi, C. Kosan, T. Moroy, D. W. Felsher, and M. Eilers (2010)
Genes & Dev.
24, 1281-1294
|Abstract »|Full Text »|PDF »
MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.
Generation of iPSCs from cultured human malignant cells.
J. E. Carette, J. Pruszak, M. Varadarajan, V. A. Blomen, S. Gokhale, F. D. Camargo, M. Wernig, R. Jaenisch, and T. R. Brummelkamp (2010)
Blood
115, 4039-4042
|Abstract »|Full Text »|PDF »
Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
S. Giuriato, M. Foisseau, E. Dejean, D. W. Felsher, T. Al Saati, C. Demur, A. Ragab, A. Kruczynski, C. Schiff, G. Delsol, et al. (2010)
Blood
115, 4061-4070
|Abstract »|Full Text »|PDF »
Review: Castration-resistant prostate cancer: new science and therapeutic prospects.
J. Bellmunt and W. K. Oh (2010)
Therapeutic Advances in Medical Oncology
2, 189-207
|Abstract »|PDF »
Refocusing the War on Cancer: The Critical Role of Personalized Treatment.
A. Potti, R. L. Schilsky, and J. R. Nevins (2010)
Science Translational Medicine
2, 28cm13
|Full Text »|PDF »
Oncogenic Signal Transduction Networks in Cancer: Relevance to Cancer Therapy.
E. Bublil, C. R. Pradeep, and Y. Yarden (2010)
Am. Assoc. Cancer Res. Educ. Book
2010, 39-42
|Full Text »|PDF »
Mitochondrial p32 Protein Is a Critical Regulator of Tumor Metabolism via Maintenance of Oxidative Phosphorylation.
V. Fogal, A. D. Richardson, P. P. Karmali, I. E. Scheffler, J. W. Smith, and E. Ruoslahti (2010)
Mol. Cell. Biol.
30, 1303-1318
|Abstract »|Full Text »|PDF »
Serious Hematologic Complications Following Erlotinib Treatment.
G. P. STATHOPOULOS, D. TRAFALIS, A. ATHANASIOU, G. BARDI, and H. CHANDRINOU (2010)
Anticancer Res
30, 973-976
|Abstract »|Full Text »|PDF »
Small-molecule signal-transduction inhibitors: targeted therapeutic agents for single-gene disorders.
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer.
D. Jackman, W. Pao, G. J. Riely, J. A. Engelman, M. G. Kris, P. A. Janne, T. Lynch, B. E. Johnson, and V. A. Miller (2010)
J. Clin. Oncol.
28, 357-360
|Abstract »|Full Text »|PDF »
Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
P. S. Hammerman, P. A. Janne, and B. E. Johnson (2009)
Clin. Cancer Res.
15, 7502-7509
|Abstract »|Full Text »|PDF »
Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.
A. W. Gramza, C. L. Corless, and M. C. Heinrich (2009)
Clin. Cancer Res.
15, 7510-7518
|Abstract »|Full Text »|PDF »
Human cancers converge at the HIF-2{alpha} oncogenic axis.
A. Franovic, C. E. Holterman, J. Payette, and S. Lee (2009)
PNAS
106, 21306-21311
|Abstract »|Full Text »|PDF »
Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells.
W. Liu, L. He, J. Ramirez, and M. J. Ratain (2009)
Clin. Cancer Res.
15, 7602-7607
|Abstract »|Full Text »|PDF »
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
C. M. Emery, K. G. Vijayendran, M. C. Zipser, A. M. Sawyer, L. Niu, J. J. Kim, C. Hatton, R. Chopra, P. A. Oberholzer, M. B. Karpova, et al. (2009)
PNAS
106, 20411-20416
|Abstract »|Full Text »|PDF »
Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology.
Deregulated GSK3{beta} Sustains Gastrointestinal Cancer Cells Survival by Modulating Human Telomerase Reverse Transcriptase and Telomerase.
W. Mai, K. Kawakami, A. Shakoori, S. Kyo, K. Miyashita, K. Yokoi, M. Jin, T. Shimasaki, Y. Motoo, and T. Minamoto (2009)
Clin. Cancer Res.
15, 6810-6819
|Abstract »|Full Text »|PDF »
Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity.
P. C.C. Liu, E. Caulder, J. Li, P. Waeltz, A. Margulis, R. Wynn, M. Becker-Pasha, Y. Li, E. Crowgey, G. Hollis, et al. (2009)
Clin. Cancer Res.
15, 6891-6900
|Abstract »|Full Text »|PDF »
Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc, SLC3A2).
P. Fogelstrand, C. C. Feral, R. Zargham, and M. H. Ginsberg (2009)
J. Exp. Med.
206, 2397-2406
|Abstract »|Full Text »|PDF »
New therapeutic advances in the management of progressive thyroid cancer.
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
Y.-K. Yoon, H.-P. Kim, S.-W. Han, H.-S. Hur, D. Y. Oh, S.-A. Im, Y.-J. Bang, and T.-Y. Kim (2009)
Mol. Cancer Ther.
8, 2526-2536
|Abstract »|Full Text »|PDF »
Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling.
M. A. Lopez-Lago, T. Okada, M. M. Murillo, N. Socci, and F. G. Giancotti (2009)
Mol. Cell. Biol.
29, 4235-4249
|Abstract »|Full Text »|PDF »
The Constitutive Active/Androstane Receptor Facilitates Unique Phenobarbital-Induced Expression Changes of Genes Involved in Key Pathways in Precancerous Liver and Liver Tumors.
J. M. Phillips, L. D. Burgoon, and J. I. Goodman (2009)
Toxicol. Sci.
110, 319-333
|Abstract »|Full Text »|PDF »
Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction.
M. Jechlinger, K. Podsypanina, and H. Varmus (2009)
Genes & Dev.
23, 1677-1688
|Abstract »|Full Text »|PDF »
Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma.
S. Komatsu, I. Imoto, H. Tsuda, K.-i. Kozaki, T. Muramatsu, Y. Shimada, S. Aiko, Y. Yoshizumi, D. Ichikawa, E. Otsuji, et al. (2009)
Carcinogenesis
30, 1139-1146
|Abstract »|Full Text »|PDF »
